ClinicalTrials.gg
CompletedNCT06588972Updated Jul 2, 2025

Analgesic Effects of a Treatment With Cannabis Sativa Extract in Patients With Knee Osteoarthritis - CANOA (Cannabis for Osteoarthritis)

A Phase 2 interventional study of Medium Chain Triglyceride solution and Cannabis Sativa in OSTEOARTHRITIS OF THE KNEE, sponsored by Federal University of Latin American Integration. Completed at 1 site in Brazil. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-07-02.

Sponsored by Federal University of Latin American Integration · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jan 2024, registered Apr 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
30 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Osteoarthritis, Knee with a site in Brazil — 12 open to participants now, 12 under way, 2 of them phase 3. Osteoarthritis, Knee · Brazil.

Enrollment
55th of 77
45 · median 66
Started
2024
with 6 others
Phase 2
6 of 79
none open now
Registered
72nd of 79
by date

Among the 79 studies in Osteoarthritis, Knee with a site in Brazil, this one is the 55th largest by enrollment of the 77 interventional ones that give a count, is one of 7 that started in 2024, is one of 6 in phase 2, and was the 72nd registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

12 of the 79 studies in Osteoarthritis, Knee with a site in Brazil are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 30 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Osteoarthritis, Knee with a site in Brazil, or all of them as a file.
02

Study summary

Osteoarthritis (OA) is the most prevalent joint disease in humans, often causing disability in affected individuals, especially the elderly. OA is characterized by mechanical joint pain, crepitus and short-term post-immobilization stiffness. OA pain has a variable pathophysiology and, despite the many pharmacological options available, its treatment is often ineffective and has significant side effects. The search for more effective and safer treatments is therefore essential in the field of OA. Among the possible treatments are substances derived from cannabis. Cannabis plants have been used for various purposes by humankind for thousands of years. Its best-known species, Cannabis sativa, has more than a hundred substances called cannabinoids or, more specifically, phytocannabinoids, the most important of which is cannabidiol (CBD). Although many pre-clinical studies indicate the usefulness of phytocannabinoids, clinical evidence for their application is currently scarce. Therefore, this project aims to investigate the effects of a CBD-rich extract of Cannabis sativa on the pain of patients with knee OA, as well as the possible adverse events of this treatment.

03

Conditions studied

  • OSTEOARTHRITIS OF THE KNEE

Keywords

  • Osteoarthritis
  • Pain
  • Cannabinoids
  • Cannabinoid safety
  • Tetrahydrocannabinol
  • Cannabidiol
04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of knee osteoarthritis, according to the ACR classification criteria (ALTMAN, 1986);
  • Have a moderate or high level of pain induced by osteoarthritis (visual analog scale scale equal to or greater than 5);
  • Voluntarily agree to take part in the study by signing the Form (ICF);
  • For women of reproductive age, a negative Beta-HCG test, and use of a method throughout the study.
  • For women of reproductive age, a negative Beta-HCG test, and use of a contraceptive method throughout the study and 3 months after its conclusion.
  • Age range of thirty (30) to seventy (70) years.

Exclusion criteria

Exclusion Criteria:

  • People with heart failure, hypertension or any heart disease;
  • People with chronic kidney disease or liver failure;
  • Patients with chronic inflammatory diseases;
  • Patients with severe psychiatric illnesses, such as severe mood disorders and psychotic disorders;
  • Current use of cannabinoids by any route of administration.
  • Pregnant women
  • Lactating women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Placebo comparator
    Group 1

    placebo (solution of Medium Chain Triglycerides, without any active ingredient)

    Dietary Supplement: Medium Chain Triglyceride solution

  • Experimental
    Group 2

    Cannabis sativa extract with a CBD (45 mg/day)

    Other: Cannabis Sativa

Interventions

  • Dietary supplementMedium Chain Triglyceride solution

    Placebo

  • OtherCannabis Sativa

    Group 2: Cannabis sativa extract with CBD (45mg/day).

06

What researchers measure

Primary outcomes

  1. Pain levels

    Change in pain levels, according to the score in the "pain" domain of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), using the Likert scale to assign a value to the answers obtained from the participants. The pain levels according to the score are 0-8 mild, greater than 8-14 moderate, greater than 14- 20 high.

    Time frame: 2 months

Secondary outcomes

  1. Short Form Health Survey (SF-12)

    Change in the Short Form Health Survey (SF-12) quality of life scores, according to the "maximal walking" and "activities of daily living" domains, where a score of 0 is the worst quality of life and 100 the best.

    Time frame: 2 months

  2. Depression

    Changes in levels of depression using the Beck Depression scale. Changes in depression levels using the Beck depression scale. The disease level values range from 0-9 indicating that the individual is not depressed, 10-18 indicating mild to moderate depression, 19-29 indicating moderate to severe depression and 30-63 indicating severe depression.

    Time frame: 2 months

  3. Adverse events

    presence of adverse events (AE) - proportion of patients with AE in the placebo and intervention groups;

    Time frame: 2 months

  4. Serious adverse events

    presence of serious adverse events (AEs) - description of the serious AEs that may appear in each group.

    Time frame: 2 months

  5. Change in sleep quality

    The Pittsburgh scale was used to see if there was any change in the participants' quality of sleep. The scale used classifies sleep quality as follows: * Good 0-4 * Bad -10 * Presence of sleep disturbance greater than 10

    Time frame: 2 months

  6. Renal Function Panel

    Used as form to identify any renal impairment in pacientes that could result in any need of adjusting the dose or need to leave the study.

    Time frame: 2 months

  7. Visual Analogue Scale (VAS)

    It is used in the healthcare field to measure the intensity of pain a person feels, usually on a scale from 0 to 10, where 0 means 'no pain' and 10 means 'the worst pain imaginable

    Time frame: 2 month

  8. Hepatic Panel

    Used to monitor liver function in patients, as pacientes are receiving an oil-based medication that may overload the liver.

    Time frame: 2 month

07

Study locations

1 site
  • Federal University of Latin American Integration
    Foz do Iguaçu, Paraná 85870-650, Brazil
08

References and documents

Publications

  • Mojoli A, Haider O, Fakih Y, Luz Goncalves MV, Zepeda Rojas B, Xaia G, Krefta E, Bicca MA, Lopes de Mari T, Ferreira CF, Cezar-Dos-Santos F, Toci AT, Nascimento FP. Effects and safety of a CBD-rich Cannabis sativa oil in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial - CANOA - cannabis for osteoarthritis. Front Pharmacol. 2025 Dec 19;16:1657065. doi: 10.3389/fphar.2025.1657065. eCollection 2025. PubMed 41487518 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Oct 2024, 9 months.

Of 43 non-industry phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 61. This study's 9 months is below that.

Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2024
First posted
Sep 19, 2024
StartActual
Jan 1, 2024
Primary completionActual
Oct 10, 2024
CompletionActual
Oct 12, 2024
Last update
Jul 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06588972
Lead sponsor
Federal University of Latin American Integration
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Jan 1, 2024
Primary completion
Oct 10, 2024
Completion
Oct 12, 2024
Last update
Jul 2, 2025

Study contacts

Francisney P Nascimento, 1
study director · Federal University of Latin American Integration

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion